GHK-Cu: Why Product Form and Route Matter

GHK-Cu is one molecule that reaches people in very different products. The form and the route (a cream on intact skin, a gel on a wound, an injectable preparation) decide which studies apply, which safety questions matter and which rules govern the product. This profile explains those differences. We do not provide dosing, preparation or administration guidance for any form.

One molecule, several product forms

GHK-Cu is the copper complex of GHK, a three-amino-acid peptide; on cosmetic labels it is listed as copper tripeptide-1 ^{Source [1]}. It appears in at least four settings:

• Finished cosmetics such as serums and creams applied to intact skin.
• Experimental wound products, so far studied mainly in animals and cells ^{Source [8]}.
• Laboratory delivery systems, including liposomes, microneedles, hydrogels and injectable depots tested in laboratory and animal studies ^{Source [2]}.
• Injectable preparations. A 2026 review written for orthopaedic and sports medicine physicians included GHK-Cu among popular injectable peptide therapies and found no clinical data supporting its use for musculoskeletal conditions ^{Source [3]}.

The same 2026 evidence review cautions that the literature often treats GHK-Cu as a single ingredient, even though its chemical state, stability and behavior depend on the formulation, and that GHK without copper, GHK-Cu and related copper peptides should not be treated as interchangeable ^{Source [2]}.

What has been studied, by form

Topical use on intact skin

Human studies are small. In a 13-person randomized study after laser resurfacing, objective measures showed no benefit, although patients using GHK-Cu products rated their improvement higher ^{Source [4]}. An 18-person split-face study reported more and thicker eyebrow hairs on the side treated with a GHK-Cu serum than on the vehicle side after 12 weeks ^{Source [5]}.

Whether the peptide crosses intact skin is unsettled. Lab studies on donated human skin range from measurable copper passage ^{Source [6]} to almost none without microneedle pretreatment ^{Source [7]}. Our guide to copper peptides in skincare covers this evidence in more detail.

Wounds and damaged skin

Wound-healing findings come mainly from animal and cell studies ^{Source [8]}. A wound removes much of the skin barrier, so these results do not describe what a cosmetic does on intact skin.

Injected or systemic use

Evidence for systemic effects comes from animals. In a mouse model of silicosis, a lung disease caused by silica dust, GHK-Cu reduced lung inflammation and scarring ^{Source [9]}. The 2026 evidence review singles this study out as the instructive exception, in which a defined preparation was given systemically and its binding partner identified directly, but stresses that it does not replace the distribution and repeat-dose safety studies an injectable product would need ^{Source [2]}.

FDA states that compounded injectable drugs containing GHK-Cu may pose a risk of immune reactions because of aggregation and peptide-related impurities, and that limited human data exist to inform safety ^{Source [10]}. When we searched ClinicalTrials.gov for "GHK-Cu" on October 18, 2026, it returned three registered studies (a wound gel, a skin patch, and a facial treatment with a booster serum), and none tested an injected GHK-Cu product ^{Source [11]}.

Why evidence does not transfer between forms

Each form meets the body differently. A cosmetic on intact skin first has to get past the skin barrier; a wound product meets damaged tissue; an injection bypasses the barrier entirely. The 2026 evidence review argues that limits on free (labile) copper should be set route by route, strictest for injectable and implanted products and least strict for products used on intact skin, and notes that copper is a recognized contact allergen in susceptible people ^{Source [2]}.

Safety conclusions are tied to form as well. When the Cosmetic Ingredient Review expert panel concluded in 2018 that tripeptide-1 and related ingredients, including copper tripeptide-1, are safe as used in cosmetics, it pointed to low use concentrations, typically below 10 parts per million, and negative safety test data ^{Source [12]}. That conclusion concerns cosmetics; it does not address injection.

So a positive cosmetic study does not support an injectable product, and an animal study of systemic GHK-Cu does not support a serum.

Regulatory status depends on the form

Checked for the United States on October 18, 2026:

• Cosmetics. Cosmetic products and ingredients other than color additives do not need FDA approval before sale, and companies are responsible for their safety ^{Source [13]}. A product whose claims show it is intended to treat a condition, rather than to change appearance, is regulated as a drug ^{Source [14]}.
• Compounded injectables. FDA keeps a page on bulk substances for compounding that may present significant safety risks (content current as of April 22, 2026). It lists GHK-Cu "for injectable routes of administration" in its section on substances previously placed in category 2 whose nominations were withdrawn by the nominators, together with the safety concerns described above ^{Source [10]}. That entry is a safety note, not an approval.
• Approved drugs. In FDA's Drugs@FDA data files (last updated October 16, 2026), no product under an approved application lists GHK-Cu as an active ingredient ^{Source [15]}.

For what these terms mean in practice, see approved, compounded, and unapproved and why product availability is not regulatory approval.

Anti-doping status

GHK-Cu is not named on the World Anti-Doping Agency's 2026 Prohibited List, which came into effect on January 1, 2026. Not being named is not the same as being permitted. The list also prohibits at all times any pharmacological substance not addressed elsewhere that has no current government approval for human therapeutic use, and its growth factor section covers other growth factor modulators affecting areas such as vascularisation and regenerative capacity, beyond the named examples ^{Source [16]}. Athletes should ask their anti-doping organization before using any GHK-Cu product.

Questions to ask about any GHK-Cu product

• What form and route is it: a finished cosmetic for skin, or something else?
• Which human studies used that same form and route, and how large were they?
• What does the label state about concentration, and what does that figure measure?
• What is its legal status where you live, for that form?

If you are considering anything other than a finished cosmetic, talk with a licensed clinician who knows your health history. Our medical disclaimer explains the limits of this site.